Skip to content Skip to footer
Q1 2025

PharmaShots’ Key Highlights of Second Quarter 2025 

Shots:   Q2’2025 highlights major acquisitions in the pharma and biotech industry along with collaboartion. The talk of the town remained Blueprint Medicines’ acquisition by Sanofi for ~$9.5B   The quarter highlighted Collaboartion, including Eli Lilly Enters a ~$1.4B Licensing Agreement with Sangamo Therapeutics for its STAC-BBB Capsid   PharmaShots brings the Quarterly digest compiling insights from…

Read more

PharmaShots’ Key Highlights of First Quarter 2025

Shots:  Q1’2025 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The talk of the town remained Intra-Cellular Therapies’ acquisition by Johnson & Johnson for ~$14.6B  The quarter highlighted breakthrough results, pivotal clinical data, including Eli Lilly and Incyte's P-III Study Data of Baricitinib to treat Alopecia Areata PharmaShots brings…

Read more